BioVie’s Breakthrough in Alzheimer’s, Parkinson’s & Long COVID

Jul 9, 2025

For biotech investors and healthcare innovators: In this episode of New to The Street, BioVie CEO Cuong Do and Chief Medical Officer Dr. Joseph Palumbo reveal groundbreaking data from trials targeting Alzheimer’s, Parkinson’s, and long COVID. Their novel therapeutic has shown:

✔️ 68{d450b60efc35a2e17361b5d57bc194208ff1ac62c46bd45a026f4271e6a4dcc4} symptom reduction in Alzheimer’s
✔️ Biological age deceleration by ~5 years
✔️ Parkinson’s patients regaining motor control
✔️ First NIH-funded trial for long COVID treatment

With three trials progressing and data expected soon, BioVie is shaping the future of neurodegenerative and post-viral disease treatment.

🏷️ Tags
#BioVie #AlzheimersTreatment #ParkinsonsResearch #LongCOVID #BiotechInvesting #Neuroinflammation #AntiInflammatory #DNARepair #BiologicalAge #BrainHealth #ClinicalTrials #HealthcareInnovation #AgingResearch #NewToTheStreet #CuongDo #JosephPalumbo #Neuroscience #LongevityScience #NIHfunded #MedicalBreakthroughs #NeurodegenerativeDiseases